Allovir Inc reports results for the quarter ended in September - Earnings Summary

Kalaris Therapeutics

02/11/2023 13:32

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 39
cents​​ per share for the quarter ended in September, higher
than the same quarter last year, when the company reported EPS
of -50 cents.  The mean expectation of five analysts for the
quarter was for a loss of 42 cents per share. Wall Street
expected results to range from -47 cents to -35 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 39
cents​.
    * The company reported a quarterly loss of $44.27 million.
    * Allovir Inc shares had fallen by 28.4% this quarter and
lost 70.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 9.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Allovir Inc is
$18.50 
This summary was machine generated from LSEG data November 2 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.42          -0.39          Beat
 Jun. 30 2023      -0.45          -0.48          Missed
 Mar. 31 2023      -0.46          -0.44          Beat
 Dec. 31 2022      -0.54          -0.37          Beat